4.2 Review

Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

期刊

MEDICINA-LITHUANIA
卷 58, 期 5, 页码 -

出版社

MDPI
DOI: 10.3390/medicina58050649

关键词

hepatocyte growth factor; c-MET; ovarian cancer; humanized monoclonal antibody; anti-cancer; therapeutics

资金

  1. National Research Foundation of Korea (NRF) - Korea government (MSIT) [2020R1F1A1065142]
  2. National Research Foundation of Korea [2020R1F1A1065142] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

This review explains the role of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumorigenesis and metastasis of ovarian cancer. Clinical studies have shown promising results using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, including ovarian cancer. Combining HGF/c-MET targeted therapy with chemotherapy drugs could be an effective strategy for treating ovarian cancer.
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据